65 273

Cited 0 times in

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.

Authors
Luomanmaki, K; Grankvist, S; Hallert, C; Jauro, I; Ketola, K; Kim, HC; Kiviniemi, H; Koskivirta, H; Sorskog, L; Vilkko, P
Citation
Journal of internal medicine, 240(2):85-92, 1996
Journal Title
Journal of internal medicine
ISSN
0954-68201365-2796
Abstract
OBJECTIVES: To compare the efficacy and safety of the low molecular weight heparin (LMWH) dalteparin with unfractionated heparin (UFH) in the acute treatment of DVT patients who had not previously received UFH.



DESIGN: An open randomized multicentre trial with blinded analysis of venograms.



SETTING: Seven hospitals in Sweden, Finland and the USA.



SUBJECTS: A total of 330 patients, of 20 years or older, with suspected DVT, verified using venography.



INTERVENTIONS: Fixed-dose dalteparin (200 IU kg-1) given as a once-daily subcutaneous injection, or aPTT adjusted i.v. UFH infusion for 6 to 10 days.



MAIN OUTCOME MEASURES: Change in Marder score in patients with confirmed DVT and two evaluable venograms; PE, bleeding events and follow-up.



RESULTS: Marder scores improved in 51% (95% CI 42-60%) of 92 patients treated with dalteparin and in 62% (95% CI 53-70%) of 98 patients treated with UFH (P = 0.152). One dalteparin-treated patient had a PE confirmed by V/Q scan; another had progressive thrombosis with swelling in the affected limb. Bleeding complications occurred in six patients in each group. One patient treated with dalteparin and five treated with UFH died during the 6-month follow-up period as a result of underlying malignancy or heart disease. The 6-month recurrence rate was low with both treatments (dalteparin, 3/97; UFH, 2/103).



CONCLUSIONS: Fixed-dose subcutaneous dalteparin given once daily from the start of treatment is of equivalent efficacy and safety to conventional UFH therapy in the routine management of DVT.
MeSH terms
AdultAgedAged, 80 and overDalteparin/*administration & dosage/adverse effectsDrug Administration ScheduleFemaleFibrinolytic Agents/*administration & dosage/adverse effectsFollow-Up StudiesHematocritHemoglobinsHeparin/*administration & dosage/adverse effectsHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedPartial Thromboplastin TimeRisk FactorsThromboembolism/etiology/prevention & controlThrombosis/blood/complications/*drug therapy
PMID
8810934
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
김, 효철
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse